GlaxoSmithKline reveals positive results from \'Zejula\' ovarian cancer trial
By Josh White
Date: Monday 15 Jul 2019
(Sharecast News) - GlaxoSmithKline announced positive results from its \'PRIMA\' phase 3 randomised, double-blind, placebo-controlled study of \'Zejula\' (niraparib) as a maintenance therapy in patients with first-line ovarian cancer following platinum-based chemotherapy on Monday.
The FTSE 100 pharmaceuticals giant said the study met its primary endpoint of a statistically-significant improvement in progression free survival for women regardless of their biomarker status.
It said the safety and tolerability profile of niraparib was consistent with previous clinical trials.
\"Almost 300,000 women around the world are diagnosed with ovarian cancer every year, yet only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy,\" said GlaxoSmithKlione\'s chief scientific officer and president of research and development Dr Hal Barron.
\"These exciting data demonstrate that Zejula has the potential to significantly benefit even more women with this devastating cancer.\"
The company said the full results from \'PRIMA\' would be presented at an upcoming scientific meeting.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN